Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 2:51 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 601–624 of 1,356 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Resolution Clear all
Recruiting Phase 1 Interventional

A Study of Amicidin-β Topical Solution for Patients With Surgical or Traumatic Wound Infections

NCT07379684
View directory record Official record
Conditions
Surgical Wound Infection, Traumatic Wound Infection
Interventions
Amicidin-β topical solution - 15 mL, Amicidin-β topical solution - 50 mL, Standard of Care (SOC)
Drug
Lead sponsor
Macro Biologics, Inc.
Industry
Eligibility
18 Years to 79 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
5
States / cities
Torrance, California • Idaho Falls, Idaho • Baltimore, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Oct 28, 2026, 2:51 AM EDT
Completed Not applicable Interventional Results available

A Multi-Center Investigation of Patient Acceptability of OPTI-FREE RepleniSH® Multi-Purpose Disinfecting Solution (MPDS)

NCT00772707
View directory record Official record
Conditions
Myopia
Interventions
Multi-Purpose Disinfecting Solution (OPTI-FREE RepleniSH), Contact Lenses
Device
Lead sponsor
Alcon Research
Industry
Eligibility
18 Years to 65 Years
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
1
States / cities
Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Sep 7, 2012 · Synced Oct 28, 2026, 2:51 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Topical Application of Cocaine HCl 4%, or 10%, or Placebo Solution in Local (Topical) Anesthesia

NCT02500836
View directory record Official record
Conditions
Any Ear Nose or Throat Conditions, With Identified Need for a Diagnostic Procedure or Surgery on or Through the Mucous Membranes of the Nasal Cavities
Interventions
Cocaine HCl 4% Topical Solution, Cocaine HCl 10% Topical Solution, Placebo Topical Solution
Drug
Lead sponsor
Lannett Company, Inc.
Industry
Eligibility
18 Years and older
Enrollment
646 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated May 16, 2017 · Synced Oct 28, 2026, 2:51 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Exploring the Effects of Corticosteroids on the Human Hippocampus

NCT03896659
View directory record Official record
Conditions
Hydrocortisone, Depression, Healthy Volunteers
Interventions
Hydrocortisone Oral, Placebo Oral Tablet
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 50 Years
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2024
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Dec 16, 2025 · Synced Oct 28, 2026, 2:51 AM EDT
Completed Phase 4 Interventional Results available

Study of Rhopressa® for the Reduction of Elevated Intraocular Pressure in Patients With Glaucoma or Ocular Hypertension in a Real-world Setting

NCT03808688
View directory record Official record
Conditions
Glaucoma, Open-Angle, Ocular Hypertension
Interventions
Netarsudil Ophthalmic Solution 0.02%
Drug
Lead sponsor
Aerie Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
261 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
22
States / cities
Huntington Beach, California • Laguna Hills, California • Petaluma, California + 18 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2020 · Synced Oct 28, 2026, 2:51 AM EDT
Terminated Phase 3 Interventional

Ribavirin to Prevent RSV Pneumonia in Bone Marrow Transplant Patients

NCT00031473
View directory record Official record
Conditions
Respiratory Syncytial Virus Infections
Interventions
Virazole (Ribavirin) Inhalation Solution
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
5 Years to 60 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2003
U.S. locations
11
States / cities
Birmingham, Alabama • Duarte, California • San Francisco, California + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2010 · Synced Oct 28, 2026, 2:51 AM EDT
Completed Not applicable Interventional Results available

Artifact-Free High-Resolution Myocardial Perfusion MRI in Subjects With Abnormal Nuclear Myocardial Perfusion Studies

NCT01949844
View directory record Official record
Conditions
Coronary Artery Disease, CAD
Interventions
regadenoson, Optimark®, Myocardial perfusion MRI
Drug · Device
Lead sponsor
Daniel S. Berman
Other
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 20, 2018 · Synced Oct 28, 2026, 2:51 AM EDT
Not listed Phase 2Phase 3 Interventional

Safety and Effectiveness of the PXL Platinum 330 System With Riboflavin Solution for Previously Untreated Corneal Ulcers

NCT05255107
View directory record Official record
Conditions
Keratitis, Corneal Ulcer
Interventions
Standard of Care Therapy + CXL + Riboflavin 0.23% L Solution, Standard of Care Therapy + Sham CXL + Artificial Tears
Combination Product · Other
Lead sponsor
Peschke GmbH
Industry
Eligibility
18 Years and older
Enrollment
468 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
12
States / cities
Littleton, Colorado • Fort Myers, Florida • Tampa, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2022 · Synced Oct 28, 2026, 2:51 AM EDT
Enrolling by invitation Not applicable Interventional

Conventional Endoscopic Techniques Versus EndoRotor® System for Necrosectomy of Walled of Necrosis

NCT04814693
View directory record Official record
Conditions
Acute Pancreatitis, Necrosis; Pancreas, Acute (Infectious)
Interventions
EndoRotor® System (Interscope, Inc., Northbridge, MA USA),, Conventional endoscopic devices (according to standards of care)
Device · Procedure
Lead sponsor
Erasmus Medical Center
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
3
States / cities
Birmingham, Alabama • San Francisco, California • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 8, 2025 · Synced Oct 28, 2026, 2:51 AM EDT
Completed Phase 2 Interventional

Safety of Pioglitazone for Hematoma Resolution In Intracerebral Hemorrhage

NCT00827892
View directory record Official record
Conditions
Intracerebral Hemorrhage
Interventions
Pioglitazone, Placebo Control
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years to 80 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 2, 2015 · Synced Oct 28, 2026, 2:51 AM EDT
Not listed Not applicable Interventional

Eyelash Prostheses Compared to 5.0% Lifitegrast BID for Dry Eye Disease.

NCT03691636
View directory record Official record
Conditions
Dry Eye
Interventions
Eyelash prostheses, 5.0% Lifitegrast Ophthalmic Solution
Device
Lead sponsor
D.E.L., LLC
Industry
Eligibility
50 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Washington, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 2, 2018 · Synced Oct 28, 2026, 2:51 AM EDT
Recruiting Not applicable Interventional

Solution-Focused Brief Therapy for Support of Psychological Distress in Adolescent and Young Adult Cancer Survivors

NCT06941324
View directory record Official record
Conditions
Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm
Interventions
Behavioral Intervention, Best Practice, Communication Intervention, Discussion, Health Promotion and Education, Interview, Questionnaire Administration
Behavioral · Other
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
15 Years to 39 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Oct 28, 2026, 2:51 AM EDT
Completed Phase 2 Interventional Results available

Study of Netarsudil Ophthalmic Solution in Japanese/Japanese-American Subjects With Open-angle Glaucoma or Ocular Hypertension

NCT03310580
View directory record Official record
Conditions
Primary Open Angle Glaucoma or Ocular Hypertension
Interventions
AR-13324 Ophthalmic Solution 0.02%, AR-13324 Ophthalmic Solution 0.04%, AR-13324 Ophthalmic Solution Placebo
Drug
Lead sponsor
Aerie Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
40
States / cities
Chandler, Arizona • Phoenix, Arizona • Azusa, California + 29 more
Source: ClinicalTrials.gov public record
Updated Dec 23, 2019 · Synced Oct 28, 2026, 2:51 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Inherited Risk Evaluation Tool (InheRET): Identifying Patients at Increased Risk for Hereditary Disease

NCT04510896
View directory record Official record
Conditions
Hereditary Cancer-Predisposing Syndrome
Interventions
InheRET, Patient Acceptance, Physician Acceptance Survey
Other
Lead sponsor
InheRET, Inc
Industry
Eligibility
18 Years and older
Enrollment
2,232 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
4
States / cities
Ann Arbor, Michigan • Flint, Michigan • Saginaw, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 30, 2021 · Synced Oct 28, 2026, 2:51 AM EDT
Completed Not applicable Interventional

Accelerated Resolution Therapy for Complicated Grief

NCT03484338
View directory record Official record
Conditions
Grief, Depressive Symptoms, Trauma, Psychological
Interventions
Accelerated Resolution Therapy
Behavioral
Lead sponsor
University of South Florida
Other
Eligibility
60 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Dec 7, 2020 · Synced Oct 28, 2026, 2:51 AM EDT
Completed Phase 1 Interventional

A Low ChloridE hyperTonic Solution for Brain Edema

NCT03204955
View directory record Official record
Conditions
Subarachnoid Hemorrhage, Acute Kidney Injury
Interventions
Sodium chloride /sodium acetate (16.4%), Sodium chloride (23.4%), PlasmaLyte
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated May 1, 2023 · Synced Oct 28, 2026, 2:51 AM EDT
Completed Phase 4 Interventional

Evaluation of Tear Film Quality and Stability in Subjects With Dry Eye Disease Using OC-01 (Varenicline Solution) Nasal Spray 0.03 mg as Compared to Vehicle Control Nasal Spray

NCT05514041
View directory record Official record
Conditions
Dry Eye Disease
Interventions
Varenicline solution, Placebo nasal spray (OC-01 Vehicle Nasal Spray)
Drug
Lead sponsor
Stephenson Eye Associates
Other
Eligibility
22 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Venice, Florida
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Oct 28, 2026, 2:51 AM EDT
Completed Phase 2 Interventional Results available

Dose-Ranging Study of the Bimatoprost Ocular Insert

NCT02358369
View directory record Official record
Conditions
Primary Open-Angle Glaucoma, Ocular Hypertension
Interventions
Bimatoprost, Timolol 0.5%, Placebo Ocular Insert, Placebo Eye Drops
Drug · Device
Lead sponsor
ForSight Vision5, Inc.
Industry
Eligibility
18 Years and older
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
10
States / cities
Fayetteville, Arkansas • Artesia, California • Newport Beach, California + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2020 · Synced Oct 28, 2026, 2:51 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

The Effectiveness of High Resolution Microendoscopy for People Living With HIV

NCT04563754
View directory record Official record
Conditions
Anal High Grade Squamous Intraepithelial Lesion
Interventions
mHRME (Mobile High resolution microendoscope), Proflavine Hemisulfate, High resolution anoscopy
Diagnostic Test · Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years and older
Enrollment
163 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2025
U.S. locations
3
States / cities
New York, New York • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 23, 2025 · Synced Oct 28, 2026, 2:51 AM EDT
Completed Phase 2 Interventional Results available

Phase 2, Multi-center, Randomized, Double- Masked and Placebo-Controlled Study of YP-P10 Ophthalmic Solution Compared to Placebo in Subjects With Dry Eye (ICECAP 1)

NCT05467293
View directory record Official record
Conditions
Dry Eye
Interventions
0.3% YP-P10 Ophthalmic Solution, 1% YP-P10 Ophthalmic Solution, YP-P10 Placebo Ophthalmic Solution (vehicle)
Drug
Lead sponsor
Yuyu Pharma, Inc.
Industry
Eligibility
Not listed
Enrollment
257 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
7
States / cities
Phoenix, Arizona • Newport Beach, California • Colorado Springs, Colorado + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2024 · Synced Oct 28, 2026, 2:51 AM EDT
Completed Phase 3 Interventional Results available

Comparing Safety and Efficacy of BOL-303259-X With Timolol Maleate in Subjects With Open-Angle Glaucoma or Ocular Hypertension

NCT01749904
View directory record Official record
Conditions
Open-Angle Glaucoma, Ocular Hypertension
Interventions
BOL-303259-X, Timolol
Drug
Lead sponsor
Bausch & Lomb Incorporated
Industry
Eligibility
18 Years and older
Enrollment
420 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Nov 7, 2018 · Synced Oct 28, 2026, 2:51 AM EDT
Completed Not applicable Interventional Results available

Use of High-Resolution Microendoscopy (HRME) in Patients With Adenocarcinoma In-Situ (AIS) of the Cervix

NCT02206048
View directory record Official record
Conditions
Cervix Carcinoma
Interventions
Proflavine, High-Resolution Microendoscopy (HRME) Imaging
Drug · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
21 Years to 64 Years · Female only
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 25, 2022 · Synced Oct 28, 2026, 2:51 AM EDT
Completed Phase 3 Interventional Results available

Imaging of Coronary Plaques in Participants Treated With Evolocumab

NCT03570697
View directory record Official record
Conditions
Coronary Artery Disease (CAD)
Interventions
Evolocumab, Placebo, Statin therapy
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
164 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
5
States / cities
Los Angeles, California • Washington D.C., District of Columbia • Elkhart, Indiana + 2 more
Source: ClinicalTrials.gov public record
Updated May 3, 2022 · Synced Oct 28, 2026, 2:51 AM EDT